Clinical Trial Update: Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the incidence and severity of diarrhea in patients with HER2-positive breast cancer treated with trastuzumab and neratinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)
• neratinib (neratinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: HER2-positive Breast Cancer, Breast Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-11-18